• Strategic JAK2 Inhibition: Translational Insights with AZD14

  2026-07-17

  This thought-leadership article explores how AZD1480, a potent and selective JAK2 inhibitor from APExBIO, empowers translational researchers to dissect and surmount STAT3-driven tumor biology challenges. By weaving mechanistic detail with strategic workflow guidance—and critically integrating recent findings on the paradoxical activation of the JAK2/STAT3 axis following IDO1 inhibition—this piece connects pathway biology, innovative assay design, and clinical translation. Building on, and advancing beyond, standard product pages and recent internal analyses, we demonstrate how AZD1480 is a cornerstone for next-generation oncology research.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-07-17

  This study demonstrates that PPARγ activation, notably via pioglitazone, regulates macrophage polarization and alleviates DSS-induced inflammatory bowel disease (IBD) by modulating the STAT-1/STAT-6 signaling axis. The findings provide mechanistic clarity for immunometabolic research, supporting translational approaches to inflammatory disease models.

• Bufalin Targets STK33: Mechanisms in Triple-Negative Breast

  2026-07-16

  Jiang et al. reveal Serine/Threonine Kinase 33 (STK33) as a direct molecular target of Bufalin in triple-negative breast cancer (TNBC), elucidating a novel mechanism of tumor suppression via STK33 degradation. These findings advance understanding of Bufalin’s mode of action and highlight STK33 as a promising target for TNBC therapy.

• HotStart 2X Green qPCR Master Mix: Precision in Gene Express

  2026-07-16

  Unlock superior specificity and sensitivity in real-time gene expression analysis with HotStart™ 2X Green qPCR Master Mix. This advanced SYBR Green qPCR master mix streamlines challenging workflows such as RNA-seq validation and biomarker quantification, while minimizing troubleshooting and maximizing reproducibility.

• CB-839 (Telaglenastat): Strategic Leverage in Cancer Metabol

  2026-07-15

  This thought-leadership article examines the mechanistic depth, translational potential, and strategic workflow implications of CB-839 (Telaglenastat) as a selective glutaminase 1 inhibitor. By integrating recent mechanistic insights—including epitranscriptomic regulation of glutamine metabolism—the article provides practical guidance for researchers aiming to optimize preclinical cancer drug evaluation. Distinct from standard product overviews, this perspective synthesizes competitive landscape analysis, experimental design recommendations, and the transformative impact of metabolic targeting in oncology.

• Cabazitaxel (XRP6258): Technical Guidance for Resistant Mode

  2026-07-15

  Cabazitaxel (XRP6258) addresses the challenge of taxane resistance in cancer research by disrupting microtubule dynamics in P-glycoprotein-expressing cell lines. It is not suitable for water-based assays or long-term solution storage and is best used in DMSO- or ethanol-based protocols requiring strict attention to solubility and handling.

• PARP7 Inhibition Restores Interferon Signaling in EAE Models

  2026-07-14

  The reference study uncovers a novel mechanism by which PARP7 inhibits type I interferon signaling through ADP-ribosylation and degradation of STAT1/STAT2, thereby exacerbating autoimmune neuroinflammation. Inhibiting PARP7 stabilized these key transcription factors and alleviated experimental autoimmune encephalomyelitis in mice, offering new therapeutic insight for multiple sclerosis research.

• Pioglitazone as a PPARγ Agonist: Applied Protocols & Innovat

  2026-07-14

  Pioglitazone stands out as a selective PPARγ agonist, offering proven workflow enhancements for metabolic, inflammatory, and neurodegenerative research models. This article delivers actionable experimental protocols, troubleshooting tips, and insight into its unique modulation of macrophage polarization—enabling researchers to translate bench evidence into robust, reproducible data.

• Plant Cell Lysis Buffer for WB and IP: Optimizing Plant Prot

  2026-07-13

  Unlock high-fidelity plant protein extraction for Western blotting and immunoprecipitation with Plant Cell Lysis Buffer for WB and IP. This guide translates innovative research insights and hands-on troubleshooting into actionable workflows, empowering next-level proteomic analysis across plant and cross-kingdom samples.

• Selonsertib (GS-4997): Precision ASK1 Inhibition in Inflamma

  2026-07-13

  Selonsertib (GS-4997) empowers researchers to dissect oxidative stress and inflammation pathways by selectively targeting ASK1. Its robust performance in both in vitro and in vivo models unlocks new approaches for fibrosis and kidney disease research, as evidenced by recent advances in lupus nephritis studies.

• 2'-O-Methyladenosine Nucleoside: Precision in RNA Modificati

  2026-07-12

  2'-O-Methyladenosine nucleoside empowers researchers to achieve highly sensitive, reproducible quantification of RNA modifications and purine metabolism, outperforming conventional nucleoside analogs in both discovery and translational assays. Leverage advanced UHPLC–MS/MS protocols and robust troubleshooting strategies for unmatched reliability in cell-based and biochemical studies.

• miR-3180 Suppresses HCC Growth via Dual Lipid Metabolic Path

  2026-07-10

  Hong et al. (2023) reveal that miR-3180 inhibits hepatocellular carcinoma (HCC) growth and metastasis by targeting both fatty acid synthesis and uptake. Their findings establish miR-3180 as a novel regulator of tumor lipid metabolism, highlighting its potential as a prognostic biomarker and therapeutic target.

• Quantifying 1-methyl Adenosine: Stable Isotope UHPLC-MS/MS A

  2026-07-09

  This article examines a recent analytical chemistry study that establishes a robust stable isotope-diluted UHPLC-MS/MS method for highly sensitive, accurate quantification of methylated purine nucleosides, including 1-methyl Adenosine, in cellular models. The method's heightened specificity and recovery rates advance RNA modification research and biomarker discovery, particularly in cancer metabolism and disease diagnostics.

• nor-NOHA Acetate: Redefining Arginase Inhibition in Tumor Im

  2026-07-09

  Explore how nor-NOHA acetate advances arginase inhibition by bridging metabolic control and immune evasion in cancer. This in-depth guide highlights distinctive mechanistic insights and practical assay implications for researchers.

• Elobixibat Hydrate: Optimizing IBAT Inhibition Workflows

  2026-07-08

  Elobixibat hydrate, a highly selective ileal bile acid transporter inhibitor, enables advanced experimental models of gut motility, metabolic modulation, and bowel preparation. This article delivers stepwise protocols, troubleshooting strategies, and comparative insights to maximize reproducibility and translational relevance in both basic and applied research.

16436 records 1/1096 page Next 12345 下5页 Last page